POZEN (POZEN), AstraZeneca (AZN) File Suit Against Dr. Reddy's (RDY)
Tweet
Share
E-mailGet Alerts POZN Hot Sheet
Join SI Premium – FREE
POZEN Inc. (Nasdaq: POZN) and AstraZeneca (NYSE: AZN) have filed a lawsuit against Dr. Reddy’s Laboratories (NYSE: RDY) in the United States District Court for the District of New Jersey, for infringement of U.S. Patent No. 6,926,907 relating to VIMOVO (naproxen / esomeprazole magnesium) delayed-release tablets.
In a Notice Letter sent to AstraZeneca and POZEN in March 2011 (Notice Letter), Dr. Reddy’s informed AstraZeneca and POZEN that it submitted an Abbreviated New Drug Application (ANDA) seeking U.S. Food and Drug Administration (FDA) approval to market a generic version of VIMOVO prior to expiration of U.S. Patent No. 6,926,907, which is one of seven patents listed in the FDA’s Orange Book for VIMOVO.
The patent expires in 2023. Under the terms of its agreement with POZEN, AstraZeneca has exercised its first right to defend the patent at issue and will take the leading role in prosecuting the infringement suit against Dr. Reddy’s.
In a Notice Letter sent to AstraZeneca and POZEN in March 2011 (Notice Letter), Dr. Reddy’s informed AstraZeneca and POZEN that it submitted an Abbreviated New Drug Application (ANDA) seeking U.S. Food and Drug Administration (FDA) approval to market a generic version of VIMOVO prior to expiration of U.S. Patent No. 6,926,907, which is one of seven patents listed in the FDA’s Orange Book for VIMOVO.
The patent expires in 2023. Under the terms of its agreement with POZEN, AstraZeneca has exercised its first right to defend the patent at issue and will take the leading role in prosecuting the infringement suit against Dr. Reddy’s.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Quantum Cyber rejects short-seller's offer to halt reports if lawsuit dropped
- Genworth Financial CEO returns from leave of absence in September
- GitLab releases version 19.3 with AI gateway and secrets tools
Create E-mail Alert Related Categories
Corporate News, FDA, LitigationSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
